HER2 is a critical prognostic and predictive marker for breast cancer, and its overexpression is strongly associated with increased tumor aggressiveness, poorer clinical outcomes, and resistance to certain therapies, including hormonal therapy and the CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy regimen [55]. Here, ERBB2 is linked to breast cancer.